anxiety/edema

This Application is a 371 of PCT/JP2005/000323, filed Jan. 6, 2005; the disclosure of which is incorporated herein by reference. DETAILED DESCRIPTION OF THE INVENTION 1. Technical Field The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is

This Application is a 371 of PCT/JP2005/000319, filed Jan. 6, 2005. DETAILED DESCRIPTION OF THE INVENTION 1. Technical Field The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety,

This Application is a 371 of PCT/JP2005/000318, filed Jan. 6, 2005; the disclosure of which is incorporated herein by reference. DETAILED DESCRIPTION OF THE INVENTION 1. Technical Field The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is

DETAILED DESCRIPTION OF THE INVENTION 1. Technical Field The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating

DETAILED DESCRIPTION OF THE INVENTION 1. Technical Field The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating

This application is a national stage entry under 35 U.S.C. .sctn. 371 of PCT/IB05/002711, filed Aug. 12, 2005 which claims benefit of Provisional Application No. 60/616,601, filed Oct. 5, 2004. This invention relates to novel compounds useful in therapy and to processes for the preparation thereof.

This invention relates to novel compounds useful in therapy and to processes for the preparation of such compounds. It also relates to compositions containing such compounds, their use and intermediates used in their preparation. WO 01/87855 discloses triazole derivatives as inhibitors of glycine

FIELD OF THE INVENTION This invention relates to novel substituted benzimidazol-2-ones. More particularly, the compounds of the present invention modulate the binding of the peptide hormone vasopressin and neuropeptide Y to their respective receptors and are therefore useful for treating conditions

TECHNICAL FIELD The present invention relates to prodrugs of (1R,2R,3R,5R,6R)-2-amino-6-fluoro-3-alkoxybicyclo[3.1.0]hexane-2,6-dicarb- oxylic acid derivatives and (1S,2R,3R,5R,6S)-2-amino-3-alkoxybicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives useful as drugs. More specifically, the present

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS This application is a National Stage Entry of International Application No. PCT/JP2017/016125, filed Apr. 18, 2017, which claims priority from Japanese Patent Application No. 2016-083147, filed Apr. 18, 2016. The entire contents of the above-referenced

FIELD OF THE INVENTION The present invention relates to bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, including derivatives, positional isomers, and prodrugs thereof, compositions comprising the same and methods of making and using the same. The present invention also relates

INDUSTRIAL FIELD OF THE APPLICATION The present invention relates to novel N,N-substituted cyclic amine compounds useful as a calcium antagonist, particularly as a nerve-selective calcium antagonist, specifically as an agent for treating and improving the diseases against which an inhibitory action

BACKGROUND ART Arginine-vasopressin (AVP) is a peptide consisting of 9 amino acids which is synthesized predominantly in the hypothalamus, and is deeply involved as a posterior pituitary hormone in the regulation of blood plasma osmotic pressure, blood pressure and amount of body fluid. To date,

FIELD OF THE INVENTION The invention generally relates to the field of deuterium-enriched pyrimidine compounds, their derivatives, enantiomers, diasteromers, solvates and pharmaceutical salts thereof for the treatment, prevention and potential cure of various diseases including chronic liver

CROSS REFERENCE TO RELATED APPLICATIONS This application is a National Stage of International Application No. PCT/JP2011/072556, filed on Sep. 30, 2011, which claims priority from Japanese Patent Application Nos. 2010-224233, filed Oct. 1, 2010 and JP 2011-054500, filed Mar. 11, 2011, the contents